| 1 |
29343029 | [microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor]. | 2018 Jan 2 |
5 |
| 2 |
26722260 | Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein. | 2015 Nov |
1 |
| 3 |
24686006 | Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. | 2014 Aug |
1 |
| 4 |
24759597 | SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. | 2014 Jul |
1 |
| 5 |
23204129 | PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. | 2013 Jan 15 |
2 |
| 6 |
23556431 | Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. | 2013 Apr 4 |
1 |
| 7 |
21474579 | HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. | 2011 May 15 |
3 |
| 8 |
20563869 | Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. | 2010 Nov |
1 |
| 9 |
18505786 | Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. | 2008 Aug 1 |
1 |
| 10 |
18829489 | Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. | 2008 Oct 1 |
2 |
| 11 |
19707354 | Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. | 2008 Jun |
1 |
| 12 |
17020995 | Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. | 2006 Oct 1 |
3 |
| 13 |
15583844 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. | 2005 Jan |
7 |
| 14 |
12446442 | Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. | 2003 Apr 15 |
8 |
| 15 |
12727828 | Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. | 2003 May 1 |
2 |
| 16 |
14614324 | Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. | 2003 Sep-Oct |
1 |